Kronos Bio had already trimmed back its headcount and pipeline in the wake of a mid-stage cancer flop. Now, it’s the company’s C-suite who are heading to the exits.

Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that match its target product profiles (TPPs).

Glenmark Pharmaceuticals has entered (PDF) the subcutaneous checkpoint inhibitor space, agreeing to pay "low double digit millions" for the chance to launch envafolimab in markets including India.

Three months after launching an investigation into the risk of secondary T-cell cancers after treatment with a CAR-T medicine, the FDA has shared more information on the cases that it has seen. But questions remained unanswered.

Last year's increase easily outstripped not only the “high single-digit” rate Abbott had predicted at the start of the year, but also the 7% growth rate it had posted in the two years leading up to 2020.

Last year proved a challenging year for contract manufacturers across the board, but Korea’s Samsung Biologics appears to have bucked the losing trend by charting what it called an “exceptional" performance. And the company sees more growth ahead.

The single-port system, dubbed da Vinci SP, has racked up clearances in the U.S. in recent years allowing it to be used in urology and transoral otolaryngology procedures. The newly bestowed CE mark allows European surgeons to use the SP platform in an even wider range of surgeries.

Two months ago, in presenting quarterly earnings, CEO Barry Greene said Sage Therapeutics was on its way to becoming a “leaner and stronger company.” Part of that mission will come to fruition later this year with a move of its headquarters in Cambridge, Massachusetts. Sage will shift from its 103,000-square-foot headquarters to a 30,567-square-foot office three blocks away, the company said in a regulatory filing.